Maintenance for acute myeloid leukemia revisited
Thomas Büchner1, Utz Krug, Wolfgang E Berdel
1Department of Medicine, Hematology and Oncology, University of Münster, Albert-Schweitzer-Str. 33, Munster, 48129, Germany. buechnr@uni-muenster.de
Current Treatment Options in Oncology
|December 7, 2007
Summary
Maintenance therapy for acute myeloid leukemia (AML) helps prevent disease regrowth and prolong remission. Evidence shows that effective AML maintenance strategies improve relapse-free survival compared to alternatives.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Maintenance therapy for acute myeloid leukemia (AML) aims to minimize residual disease and prevent relapse.
- Historically, prolonged myelosuppressive maintenance, exemplified by the CALGB protocol, has been a therapeutic standard.
- Lack of postremission therapy is associated with suboptimal durable remissions in AML.
Purpose of the Study:
- To evaluate the efficacy of maintenance treatment in acute myeloid leukemia (AML).
- To compare maintenance strategies with alternative postremission therapies.
- To assess the feasibility and safety of maintenance therapy in achieving long-term remissions.
Main Methods:
- Review of historical data and clinical trial outcomes regarding AML maintenance therapy.
- Analysis of studies comparing different maintenance dosages and durations.
- Examination of data on patient compliance and maintenance-related mortality.
Main Results:
- Intensive maintenance regimens, including classic CALGB-type protocols, improve relapse-free survival in AML.
- Studies failing to show benefit often involved low-dose or short-duration maintenance.
- Maintenance therapy is feasible and compliant in patients achieving long-term remissions, with a competitive death rate.
Conclusions:
- Postremission therapy, particularly effective maintenance, is crucial for durable remissions in AML.
- Optimized maintenance strategies demonstrate significant benefits over alternatives.
- Further assessment via prospective trials or networking is needed to establish the relative value of maintenance for AML.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...